文献速递胸部肿瘤放疗

加速大分割放疗联合化疗治疗不可手术局部晚期非小细胞肺癌:长期随访的II期试验最终结果

Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up.
PubMed 文献 · Radiat Oncol · 2019-06-24

这项前瞻性II期试验评估加速大分割放疗(AHR)联合化疗治疗不可手术局部晚期非小细胞肺癌(NSCLC),2009年至2012年入组23例、17例可评估,总缓解率82%,中位随访87个月,中位局部无进展生存19.8个月、无转移生存9.7个月、总生存23个月;因入组缓慢试验在首次计划中期分析前关闭。

要点

  • AHR联合化疗总缓解率82%,中位总生存23个月。
  • 急性G4中性粒细胞减少70%,晚期G3呼吸困难24%。
  • 试验因入组缓慢提前关闭,仅17例可评估。

核心结论

  • AHR联合化疗在不可手术局部晚期NSCLC中可行,未出现严重副作用,患者接受度高。

研究设计与样本

  • 前瞻性II期试验,2009年1月至2012年1月入组23例不可手术局部晚期NSCLC患者,17例可评估。
  • 治疗方案为诱导化疗(顺铂和多西他赛)、托姆刀AHR及巩固化疗。
  • 处方剂量为肿瘤参考等剂量线(60-70%)30 Gy/5每日分次,临床受累淋巴结25 Gy/5每日分次。
  • 主要终点为缓解率(RR),次要终点为急性和晚期副作用、局部无进展生存(PFS)、无转移生存(MFS)和总生存(OS)。
  • 试验因入组缓慢在首次计划中期分析前关闭。

主要发现

  • 总缓解率为82%。
  • 中位随访87个月(范围6-87),局部PFS为19.8个月(95%CI 9.7-未达到)。
  • MFS为9.7个月(95%CI 5.8-46.0),OS为23个月(95%CI 8.4-48.4)。
  • 70%患者发生急性G4中性粒细胞减少,24%发生G4白细胞减少,24%发生G3感觉异常,4%发生G3心律失常,4%化疗后死亡。
  • 晚期毒性为24%G3呼吸困难。

关键数值与推荐

  • 肿瘤处方剂量为参考等剂量线(60-70%)30 Gy/5每日分次。
  • 临床受累淋巴结处方剂量为25 Gy/5每日分次。
  • 总缓解率82%,中位局部PFS 19.8个月(95%CI 9.7-未达到)。
  • 中位MFS 9.7个月(95%CI 5.8-46.0),中位OS 23个月(95%CI 8.4-48.4)。
  • 急性G4中性粒细胞减少70%,晚期G3呼吸困难24%。

临床怎么用

  • AHR联合化疗可作为不可手术局部晚期NSCLC的可行治疗选择,但需注意急性血液学毒性。
  • 治疗前应评估患者对高强度急性毒性的耐受性,尤其是G4中性粒细胞减少风险。
  • 长期随访提示局部控制与生存数据,但样本量小且试验提前关闭,结果需谨慎解读。

局限性

  • 试验因入组缓慢在首次计划中期分析前关闭,仅17例可评估。
  • 样本量小,结果可能不稳健。
  • 非随机设计,无法与常规分割放化疗直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concurrent chemotherapy and radiation using conventional fractionation is the standard treatment for inoperable, locally advanced non-small-cell lung cancer (NSCLC). We tested accelerated hypofractionated radiotherapy (AHR) and chemotherapy for the treatment of locally advanced NSCLC. METHODS: Eligible patients with locally advanced NSCLC were treated with induction chemotherapy (cisplatin and docetaxel), followed by AHR using tomotherapy and consolidation chemotherapy. The prescribed doses were 30 Gy/5 daily fractions at the reference isodose (60-70%) to the tumor, and 25 Gy/5 daily fractions to the clinically involved lymph nodes. The primary end-point was response rate (RR); the secondary end-points were acute and late side-effects, local progression-free survival (PFS), metastasis-free survival (MFS) and overall survival (OS). This trial closed before the first planned interim analysis due to poor accrual. RESULTS: From January 2009 to January 2012, 17 of the 23 enrolled patients were evaluable. Treatment yielded an overall RR of 82%. Median follow-up was 87 months (range: 6-87), local PFS was 19.8 months (95% CI 9.7 - not reached), MFS was 9.7 months (95% CI 5.8-46.0) and OS was 23 months (95% CI 8.4-48.4). 70% of patients experienced acute G4 neutropenia, 24% G4 leukopenia, 24% G3 paresthesia, 4% G3 cardiac arrythmia, 4% underwent death after chemotherapy. Late toxicity was represented by 24% dyspnea G3. CONCLUSIONS: AHR combined with chemotherapy is feasible with no severe side-effects, and it appears highly acceptable by patients. TRIAL REGISTRATION: This study is registered with the EudractCT registration 2008-006525-14 . Registered on 9 December 2008.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Parisi E, Genestreti G, Sarnelli A, et al. Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. Radiat Oncol. 2019. PMID: 31234868. doi:10.1186/s13014-019-1317-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。